PB1315 Weight-Band Dosing with Mim8: Using Modelling to Support a Streamlined Approach to Haemophilia A Treatment

Autor: Kreilgaard, M., Matytsina, I., Persson, P.

Publikováno v: In Research and Practice in Thrombosis and Haemostasis October 2023 7 Supplement 2

FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic.

Autor: Lentz SR; Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA. Electronic address: steven-lentz@uiowa.edu., Chowdary P; Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK., Gil L; Department of Hematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland., Lopez-Jaime FJ; Hospital Universitario Regional de Málaga, Málaga, Spain., Mahlangu J; University of the Witwatersrand, National Health Laboratory Service, and Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa., Matytsina I; Novo Nordisk A/S, Søborg, Denmark., Nielsen AL; Novo Nordisk A/S, Søborg, Denmark., Windyga J; Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.

Publikováno v: Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2024 Apr; Vol. 22 (4), pp. 990-1000. Date of Electronic Publication: 2023 Dec 22.

Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A

Autor: Tiede A, Cid AR, Goldmann G, Jiménez-Yuste V, Pluta M, Lissitchkov T, May M, Matytsina I, Miljic P, Pabinger I, Persson P

Publikováno v: THROMBOSIS AND HAEMOSTASIS
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Factor VIII (FVIII) products are usually dosed according to body weight (BW). This may lead to under- or over-dosing in underweight or obese patients, respectively.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::b939cafd9b3f14b10700a16bb0748d47
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=11582

Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.

Autor: Escuriola Ettingshausen C; HZRM Hämophilie Zentrum Rhein Main GmbH, Mörfelden-Walldorf, Germany., Katsarou O; Haemophilia Centre, Laiko Hospital, Athens, Greece., Kotnik BF; University Children's Hospital, Ljubljana, Slovenia., Borel Derlon A; CHU de Caen - Hôpital de la Côte de Nacre, Caen, France., Schwarz R; Landes Frauen - und Kinderklinik, Linz, Austria., Ypma PF; Department of Hematology, Hagaziekenhuis, The Hague, The Netherlands., Matytsina I; Novo Nordisk A/S, Søborg, Denmark., Dey S; Novo Nordisk Service Centre India Private Ltd., Bangalore, India., Schutgens REG; Van Creveldkliniek, University Medical Centre and University, Utrecht, The Netherlands.

Publikováno v: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2022 Jan; Vol. 28 (1), pp. 46-54. Date of Electronic Publication: 2021 Nov 17.

Economic Burden of Haemophilia from a Societal Perspective: A Scoping Review.

Autor: El-Sayed AA; Public Health Institute, Faculty of Health, Liverpool John Moores University, Liverpool, UK.; Medical Affairs Department, Novo Nordisk Egypt, Cairo, Egypt., Bolous NS; Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN, USA. nancy.bolous@stjude.org.

Publikováno v: PharmacoEconomics - open [Pharmacoecon Open] 2024 Nov 15. Date of Electronic Publication: 2024 Nov 15.